SCHEMBL6445408

SCHEMBL6445408

NC(=O)c1nnc(-c2ccc(F)c3c(C(=O)C(=O)N4CCN(C(=O)c5ccccc5)CC4)c[nH]c23)[nH]1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 5/20 0.50
CYP3A4 P08684 3/20 0.45
CYP2C19 P33261 6/20 0.43
CYP2D6 P10635 5/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2C8 P10632 1/20 0.43
CYP2B6 P20813 1/20 0.43
KCNH2 Q12809 1/20 0.43
BTK Q06187 5/20 0.37
KIT P10721 2/20 0.37
AURKA O14965 1/20 0.37
JAK2 O60674 1/20 0.37
LCK P06239 1/20 0.37
LYN P07948 1/20 0.37
CDK2 P24941 1/20 0.37
TYK2 P29597 1/20 0.37
TEC P42680 1/20 0.37
TXK P42681 1/20 0.37
BMX P51813 1/20 0.37
ITK Q08881 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6466537 0.88 CYP2C9 (0.49) CYP2C9CYP3A4CYP2C19CYP2D6CYP1A2
SCHEMBL6444611 0.86 CYP2C9 (0.47) CYP2C9CYP3A4CYP2C19CYP2D6CYP1A2
SCHEMBL6442450 0.85 CYP2C9 (0.51) CYP2C9CYP3A4CYP2C19CYP2D6CYP1A2
SCHEMBL6441386 0.85 CYP2C9 (0.46) CYP2C9CYP3A4CYP2C19CYP2D6CYP1A2
SCHEMBL6442684 0.84 CYP2C9 (0.49) CYP2C9CYP3A4CYP2C19CYP2D6CYP1A2
SCHEMBL6442552 0.84 CYP2C9 (0.53) CYP2C9CYP3A4CYP2C19CYP2D6CYP1A2
SCHEMBL6441736 0.83 CYP2C9 (0.53) CYP2C9CYP3A4CYP2C19CYP2D6CYP1A2
SCHEMBL6445442 0.82 CYP2C9 (0.48) CYP2C9CYP3A4CYP2C19CYP2D6CYP1A2
SCHEMBL6445540 0.82 CYP2C9 (0.48) CYP2C9CYP3A4CYP2C19CYP2D6CYP1A2
SCHEMBL6445221 0.82 CYP2C9 (0.54) CYP2C9CYP3A4CYP2C19CYP2D6CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2002004440-A9 COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED INDOLEOXOACETIC PIPERAZINE DERIVATIVES BRISTOL MYERS SQUIBB CO (US) 2005-11-03 WO claimed
EP-1299382-B1 COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED INDOLEOXOACETIC PIPERAZINE DERIVATIVES BRISTOL MYERS SQUIBB CO (US) 2005-09-21 EP claimed
EP-1299382-A4 COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED INDOLEOXOACETIC PIPERAZINE DERIVATIVES BRISTOL MYERS SQUIBB CO (US) 2004-02-11 EP claimed
US-20030069245-A1 Composition and antiviral activity of substituted indoleoxoacetic piperazine derivatives VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) 2003-04-10 US claimed
EP-1299382-A1 COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED INDOLEOXOACETIC PIPERAZINE DERIVATIVES BRISTOL-MYERS SQUIBB COMPANY (US) 2003-04-09 EP claimed
WO-2002004440-A1 COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED INDOLEOXOACETIC PIPERAZINE DERIVATIVES BRISTOL-MYERS SQUIBB COMPANY (US) 2002-01-17 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069245-A1 Composition and antiviral activity of substituted indoleoxoacetic piperazine derivatives IDO1, IDO2, ITPA CYP2C9 2370/4885CYP3A4 469/4885CYP2C19 1624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.